- Home
- ROIV vs EDU Comparison
ROIV vs EDU Comparison
Compare ROIV & EDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- EDU
- Stock Information
- Founded
- ROIV 2014
- EDU 1993
- Country
- ROIV United Kingdom
- EDU China
- Employees
- ROIV N/A
- EDU N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- EDU Other Consumer Services
- Sector
- ROIV Health Care
- EDU Real Estate
- Exchange
- ROIV Nasdaq
- EDU Nasdaq
- Market Cap
- ROIV 7.8B
- EDU 7.3B
- IPO Year
- ROIV N/A
- EDU 2006
- Fundamental
- Price
- ROIV $11.45
- EDU $46.64
- Analyst Decision
- ROIV Buy
- EDU Hold
- Analyst Count
- ROIV 4
- EDU 4
- Target Price
- ROIV $17.50
- EDU $48.50
- AVG Volume (30 Days)
- ROIV 5.4M
- EDU 864.5K
- Earning Date
- ROIV 08-07-2025
- EDU 07-30-2025
- Dividend Yield
- ROIV N/A
- EDU 1.24%
- EPS Growth
- ROIV N/A
- EDU 27.46
- EPS
- ROIV N/A
- EDU 2.29
- Revenue
- ROIV $29,053,000.00
- EDU $4,793,786,000.00
- Revenue This Year
- ROIV $2.64
- EDU $13.57
- Revenue Next Year
- ROIV $378.09
- EDU $13.00
- P/E Ratio
- ROIV N/A
- EDU $20.49
- Revenue Growth
- ROIV N/A
- EDU 18.73
- 52 Week Low
- ROIV $8.73
- EDU $40.66
- 52 Week High
- ROIV $13.06
- EDU $87.26
- Technical
- Relative Strength Index (RSI)
- ROIV 57.83
- EDU 46.54
- Support Level
- ROIV $10.89
- EDU $46.24
- Resistance Level
- ROIV $11.79
- EDU $48.04
- Average True Range (ATR)
- ROIV 0.35
- EDU 1.05
- MACD
- ROIV 0.01
- EDU -0.06
- Stochastic Oscillator
- ROIV 62.57
- EDU 40.26
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EDU New Oriental Education & Technology Group Inc.
New Oriental is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation, consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.